2018-2023 Global Metabolic Syndrome Market Report (Status and Outlook)
Published On: October 2018
 
Report ID:350363
 
 
Pages: 133




In this report, LP Information studies the present scenario (with the base year being 2017) and the growth prospects of global Metabolic Syndrome market for 2018-2023.

Metabolic syndrome is a cluster of conditions — increased blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol or triglyceride levels — that occur together, increasing your risk of heart disease, stroke and diabetes.

One of the upcoming trends gaining traction in the market is the increasing focus on oral insulin therapies. Till now, insulin injections were mostly administered through subcutaneous tissues, but this route of application is associated with risk of infection and hypersensitivity reactions, emboli, high cost, and injection site pain. Also, several needle-phobic individuals hesitate to adopt this route of administration. This paved the way for extensive research in the development of oral insulin. The oral form of insulin prevents the unpleasantness of insulin injections and other complications associated with the existing therapies. Moreover, oral administration of insulin ensures increased patient comfort and compliance, reduced risk of infection, simpler application, and is cost-effective.

Over the next five years, LPI(LP Information) projects that Metabolic Syndrome will register a 5.2% CAGR in terms of revenue, reach US$ 33400 million by 2023, from US$ 24600 million in 2017.

This report presents a comprehensive overview, market shares and growth opportunities of Metabolic Syndrome market by product type, application, key companies and key regions.

To calculate the market size, LP Information considers value generated from the sales of the following segments:

Segmentation by product type:

Diabetes

Obesity

Lysosomal storage diseases

Segmentation by application:

Hospital

Clinic

Others

We can also provide the customized separate regional or country-level reports, for the following regions:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Spain

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report:

Novo Nordisk

Sanofi

Merck

AstraZeneca

Eli Lily

AbbVie

Actelion Pharmaceuticals

Adocia

Aegerion Pharmaceuticals

Akros Pharma

Alnylam Pharmaceuticals

Amarin

nAmgen

Amicus Therapeutics

Arbutus Biopharma

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives

To study and analyze the global Metabolic Syndrome market size by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.

To understand the structure of Metabolic Syndrome market by identifying its various subsegments.

Focuses on the key global Metabolic Syndrome players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.

To analyze the Metabolic Syndrome with respect to individual growth trends, future prospects, and their contribution to the total market.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

To project the size of Metabolic Syndrome submarkets, with respect to key regions (along with their respective key countries).

To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.

Table of Contents

2018-2023 Global Metabolic Syndrome Market Report (Status and Outlook)

1 Scope of the Report

1.1 Market Introduction

1.2 Research Objectives

1.3 Years Considered

1.4 Market Research Methodology

1.5 Economic Indicators

1.6 Currency Considered

2 Executive Summary

2.1 World Market Overview

2.1.1 Global Metabolic Syndrome Market Size 2013-2023

2.1.2 Metabolic Syndrome Market Size CAGR by Region

2.2 Metabolic Syndrome Segment by Type

2.2.1 Diabetes

2.2.2 Obesity

2.2.3 Hypercholesterolemia

2.2.4 Lysosomal storage diseases

2.3 Metabolic Syndrome Market Size by Type

2.3.1 Global Metabolic Syndrome Market Size Market Share by Type (2013-2018)

2.3.2 Global Metabolic Syndrome Market Size Growth Rate by Type (2013-2018)

2.4 Metabolic Syndrome Segment by Application

2.4.1 Hospital

2.4.2 Clinic

2.4.3 Others

2.5 Metabolic Syndrome Market Size by Application

2.5.1 Global Metabolic Syndrome Market Size Market Share by Application (2013-2018)

2.5.2 Global Metabolic Syndrome Market Size Growth Rate by Application (2013-2018)

3 Global Metabolic Syndrome by Players

3.1 Global Metabolic Syndrome Market Size Market Share by Players

3.1.1 Global Metabolic Syndrome Market Size by Players (2016-2018)

3.1.2 Global Metabolic Syndrome Market Size Market Share by Players (2016-2018)

3.2 Global Metabolic Syndrome Key Players Head office and Products Offered

3.3 Market Concentration Rate Analysis

3.3.1 Competition Landscape Analysis

3.3.2 Concentration Ratio (CR3, CR5 and CR10) (2016-2018)

3.4 New Products and Potential Entrants

3.5 Mergers & Acquisitions, Expansion

4 Metabolic Syndrome by Regions

4.1 Metabolic Syndrome Market Size by Regions

4.2 Americas Metabolic Syndrome Market Size Growth

4.3 APAC Metabolic Syndrome Market Size Growth

4.4 Europe Metabolic Syndrome Market Size Growth

4.5 Middle East & Africa Metabolic Syndrome Market Size Growth

5 Americas

5.1 Americas Metabolic Syndrome Market Size by Countries

5.2 Americas Metabolic Syndrome Market Size by Type

5.3 Americas Metabolic Syndrome Market Size by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Key Economic Indicators of Few Americas Countries

6 APAC

6.1 APAC Metabolic Syndrome Market Size by Countries

6.2 APAC Metabolic Syndrome Market Size by Type

6.3 APAC Metabolic Syndrome Market Size by Application

6.4 China

6.5 Japan

6.6 Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 Key Economic Indicators of Few APAC Countries

7 Europe

7.1 Europe Metabolic Syndrome by Countries

7.2 Europe Metabolic Syndrome Market Size by Type

7.3 Europe Metabolic Syndrome Market Size by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

7.9 Spain

7.10 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa

8.1 Middle East & Africa Metabolic Syndrome by Countries

8.2 Middle East & Africa Metabolic Syndrome Market Size by Type

8.3 Middle East & Africa Metabolic Syndrome Market Size by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 Market Drivers, Challenges and Trends

9.1 Market Drivers and Impact

9.1.1 Growing Demand from Key Regions

9.1.2 Growing Demand from Key Applications and Potential Industries

9.2 Market Challenges and Impact

9.3 Market Trends

10 Global Metabolic Syndrome Market Forecast

10.1 Global Metabolic Syndrome Market Size Forecast (2018-2023)

10.2 Global Metabolic Syndrome Forecast by Regions

10.2.1 Global Metabolic Syndrome Forecast by Regions (2018-2023)

10.2.2 Americas Market Forecast

10.2.3 APAC Market Forecast

10.2.4 Europe Market Forecast

10.2.5 Middle East & Africa Market Forecast

10.3 Americas Forecast by Countries

10.3.1 United States Market Forecast

10.3.2 Canada Market Forecast

10.3.3 Mexico Market Forecast

10.3.4 Brazil Market Forecast

10.4 APAC Forecast by Countries

10.4.1 China Market Forecast

10.4.2 Japan Market Forecast

10.4.3 Korea Market Forecast

10.4.4 Southeast Asia Market Forecast

10.4.5 India Market Forecast

10.4.6 Australia Market Forecast

10.5 Europe Forecast by Countries

10.5.1 Germany Market Forecast

10.5.2 France Market Forecast

10.5.3 UK Market Forecast

10.5.4 Italy Market Forecast

10.5.5 Russia Market Forecast

10.5.6 Spain Market Forecast

10.6 Middle East & Africa Forecast by Countries

10.6.1 Egypt Market Forecast

10.6.2 South Africa Market Forecast

10.6.3 Israel Market Forecast

10.6.4 Turkey Market Forecast

10.6.5 GCC Countries Market Forecast

10.7 Global Metabolic Syndrome Forecast by Type

10.8 Global Metabolic Syndrome Forecast by Application

11 Key Players Analysis

11.1 Novo Nordisk

11.1.1 Company Details

11.1.2 Metabolic Syndrome Product Offered

11.1.3 Novo Nordisk Metabolic Syndrome Revenue, Gross Margin and Market Share (2016-2018)

11.1.4 Main Business Overview

11.1.5 Novo Nordisk News

11.2 Sanofi

11.2.1 Company Details

11.2.2 Metabolic Syndrome Product Offered

11.2.3 Sanofi Metabolic Syndrome Revenue, Gross Margin and Market Share (2016-2018)

11.2.4 Main Business Overview

11.2.5 Sanofi News

11.3 Merck

11.3.1 Company Details

11.3.2 Metabolic Syndrome Product Offered

11.3.3 Merck Metabolic Syndrome Revenue, Gross Margin and Market Share (2016-2018)

11.3.4 Main Business Overview

11.3.5 Merck News

11.4 AstraZeneca

11.4.1 Company Details

11.4.2 Metabolic Syndrome Product Offered

11.4.3 AstraZeneca Metabolic Syndrome Revenue, Gross Margin and Market Share (2016-2018)

11.4.4 Main Business Overview

11.4.5 AstraZeneca News

11.5 Eli Lily

11.5.1 Company Details

11.5.2 Metabolic Syndrome Product Offered

11.5.3 Eli Lily Metabolic Syndrome Revenue, Gross Margin and Market Share (2016-2018)

11.5.4 Main Business Overview

11.5.5 Eli Lily News

11.6 AbbVie

11.6.1 Company Details

11.6.2 Metabolic Syndrome Product Offered

11.6.3 AbbVie Metabolic Syndrome Revenue, Gross Margin and Market Share (2016-2018)

11.6.4 Main Business Overview

11.6.5 AbbVie News

11.7 Actelion Pharmaceuticals

11.7.1 Company Details

11.7.2 Metabolic Syndrome Product Offered

11.7.3 Actelion Pharmaceuticals Metabolic Syndrome Revenue, Gross Margin and Market Share (2016-2018)

11.7.4 Main Business Overview

11.7.5 Actelion Pharmaceuticals News

11.8 Adocia

11.8.1 Company Details

11.8.2 Metabolic Syndrome Product Offered

11.8.3 Adocia Metabolic Syndrome Revenue, Gross Margin and Market Share (2016-2018)

11.8.4 Main Business Overview

11.8.5 Adocia News

11.9 Aegerion Pharmaceuticals

11.9.1 Company Details

11.9.2 Metabolic Syndrome Product Offered

11.9.3 Aegerion Pharmaceuticals Metabolic Syndrome Revenue, Gross Margin and Market Share (2016-2018)

11.9.4 Main Business Overview

11.9.5 Aegerion Pharmaceuticals News

11.10 Akros Pharma

11.10.1 Company Details

11.10.2 Metabolic Syndrome Product Offered

11.10.3 Akros Pharma Metabolic Syndrome Revenue, Gross Margin and Market Share (2016-2018)

11.10.4 Main Business Overview

11.10.5 Akros Pharma News

11.11 Alnylam Pharmaceuticals

11.12 Amarin

11.13 nAmgen

11.14 Amicus Therapeutics

11.15 Arbutus Biopharma

12 Research Findings and Conclusion




Please fill the form below, to recieve the report sample

Name*
Email*
Phone*
Name of the Company*
Title / Designation*
Country*
Your specific requirements*
Human Verification*

Please fill the form below for enquiry

Name*
Email*
Phone*
Name of the Company*
Title / Designation*
Country*
Your specific requirements*
Human Verification*
   Our Clients
  • \


Copyright © 2020 Fior Market Research LLP, All Rights Reserved.